Selling, General, and Administrative Costs: Takeda Pharmaceutical Company Limited vs Rhythm Pharmaceuticals, Inc.

Takeda vs. Rhythm: A Decade of SG&A Expense Trends

__timestampRhythm Pharmaceuticals, Inc.Takeda Pharmaceutical Company Limited
Wednesday, January 1, 20141213000612613000000
Thursday, January 1, 20153425000650773000000
Friday, January 1, 20166311000619061000000
Sunday, January 1, 20179518000628106000000
Monday, January 1, 201828080000717599000000
Tuesday, January 1, 201936550000964737000000
Wednesday, January 1, 202046125000875663000000
Friday, January 1, 202168486000886361000000
Saturday, January 1, 202292032000997309000000
Sunday, January 1, 20231175320001053819000000
Monday, January 1, 20241053819000000
Loading chart...

In pursuit of knowledge

A Tale of Two Pharmaceutical Giants: Takeda vs. Rhythm

In the ever-evolving pharmaceutical landscape, understanding the financial dynamics of industry leaders is crucial. Takeda Pharmaceutical Company Limited, a Japanese titan, and Rhythm Pharmaceuticals, Inc., a burgeoning American firm, present a fascinating contrast in their Selling, General, and Administrative (SG&A) expenses over the past decade.

From 2014 to 2023, Takeda's SG&A expenses have shown a steady increase, peaking at over 1 trillion yen in 2023, reflecting its expansive global operations. In contrast, Rhythm Pharmaceuticals, with its focus on niche markets, has seen its SG&A expenses grow from a modest 1.2 million dollars in 2014 to approximately 118 million dollars in 2023, marking a staggering 9,600% increase.

This data highlights the diverse strategies of these companies: Takeda's broad market reach versus Rhythm's targeted approach. Such insights are invaluable for investors and industry analysts alike.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025